Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -1.45% 6.80 139,669 14:45:50
Bid Price Offer Price High Price Low Price Open Price
6.60 7.00 6.90 6.80 6.90
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.80 -0.13 7
Last Trade Time Trade Type Trade Size Trade Price Currency
15:28:15 O 6,000 6.60 GBX

Physiomics (PYC) Latest News

More Physiomics News
Physiomics Investors    Physiomics Takeover Rumours

Physiomics (PYC) Discussions and Chat

Physiomics Forums and Chat

Date Time Title Posts
20/6/202115:47Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni9,741
17/6/202107:23PHYSIOMICS plc Virtual Tumor platform4,957
28/3/202122:05Physiomics PYC 2021 DISCUSSION (MODERATED)5
22/12/202011:363 Years ago today2
29/11/202014:533 Years ago today-

Add a New Thread

Physiomics (PYC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Physiomics trades in real-time

Physiomics (PYC) Top Chat Posts

Physiomics Daily Update: Physiomics Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 6.90p.
Physiomics Plc has a 4 week average price of 6.20p and a 12 week average price of 5.40p.
The 1 year high share price is 17.10p while the 1 year low share price is currently 4.65p.
There are currently 97,334,778 shares in issue and the average daily traded volume is 1,906,806 shares. The market capitalisation of Physiomics Plc is £6,618,764.90.
davevt: Dlg, 'a huge collaboration'. Hardly. Dosemerx is a dosing app, with hundreds of drugs on it. Who do you think did all the dose prediction for those? wasn't pyc was it. Doseme are only using pycs algorithm for Doxcetel because pyc already made it in the past.
the stigologist: PYC Chart setting up nicely In the meantime nice to see Valirx VAL this past week publicly talk about how Physiomics' data modelling helps them gain great insight and analytics on their own peptide VAL201 Valirx are one of Physiomics' smallest clients but PYC can earn a £6m bounty if/when VAL201 is commercially licensed by VAL PYC also work with much bigger bios/pharmas like Bicycle Therapeutics, Astellas, Merck etc (albeit on consultancy based fee arrangements not big upside risk sharing bonus remuneration as with VAL) However the transformational news due/imminent will come with move into SOFTWARE licensing/royalty based monetisation of their Virtual Tumour modelling expertise with Companies like $1bn+ Mkt Cap US healthcare player Tabula Rasa (TRHC) and developing that software in upcoming NHS Clinical Trial at PTTU (Portsmouth Technology Trial Unit) Do check out this 2 minute bit from Valirx talking about how Physiomics help them develop their drug more efficiently by targeting the right biomarkers and patient groups in clinical trials. htTps://
davevt: No, I'm looking to the future when you've sold out and someone has replaced you telling us all this is the best thing since sliced bread. Nothing you are ramping hasn't been said before, yet every year as pyc get left more and more behind, the share price keeps stalling. Maybe you should have read the rest, you could have learnt something from us experienced people about this company.
davevt: No they can't ditch them after the initial pre clinical because they are relying on pycs model to proceed into the clinical trial. If they ditched them they would have thrown away 4 years work and have to start again, from scratch. They haven't come a long way with their technology, it's now so old that their patents have expired. Remember pyc only do dose prediction for cancer drugs...all the other big Biotech companies do dose prediction for cancer drugs, and all other types of drugs. Hence why pyc has only managed 3 customers in 3 years, and you now see many of the contracts are freebies trying to get business. But regardless, none of this is important, and even if I agreed with you and everyone wanted to use them, it doesn't matter, and this is why.. Pyc have pretty much a set menu of pricing. Around 35k for a pre clinical model, around 150k for a clinical model (but you can't get to clinical stage until you've done the pre clinical, and the years worth of testing, like Merck did) Right, so, how many working cancer drugs do you think EVERYONE has produced every year? A handful, if that? Right, so even if pyc got ALL the business they still never make any worthwhile income. And that's why they don't. They don't get all the customers (why go to a company that can only model one of your drugs when others can model more of your drugs) and they can't charge much if they do. We get people like you on here every year saying 'next year will be pycs year!' 'Jim's decision to come to physiomics' mean the fat salary and share options you can pull from it being a floated company? Always next year eh 🤣
davevt: 'davevt, so the existing relationship with Merck has nothing to do with Jim? You are telling me that it doesn't take any effort and work to maintain and strengthen relationships?' OK, seems I'll have to write It simpler as you didn't understand the first time. Merck paid pyc for many years to do modelling for their three cancer drugs in pre clinical trials. Once those pre clinical trials are over, Merck HAVE to still use pyc for their clinical trial modelling. The clinical model relies on the pre clinical data. It would have happened anyway, Jim or no Jim. There is nothing to 'maintain', Merck are tied in using pyc until those clinical trials are over, which is a few years. What you should be concerned with is how little new business they have had in 3 years. Jim worked for Glaxo and couldn't get even them to use pyc. All the other big Biotech companies do everything pyc do and so so so much more, hence the big revenues and ALL the big pharma on board. You're just another clueless idiot who doesn't actually know what this company does.
davevt: 'He' didn't secure a multi year agreement with Merck. Let me educate you on the processes of this company. Merck had been doing pre clinical work with pyc for years, since 2013 if I remember correctly. When pre clinical is over, the next step is clinical stage. That's why Mercks larger agreement was around 500k euro, as they had 3 drugs in trials, of which pyc charge around 150k for clinical trial modelling for each drug. So Jim didn't 'orchestrate' any of this, it was Merck's standard progression to the next stage. What about those companies? They are 3 new ones in THREE YEARS, and there is no 'partnership' with tabula, they are simply using pycs algorithm for one particular drug in their app. and comments such as 'they have worked with' blah blah etc, is irrelevant. They are going to be working with the biggest names, because who else are they going to be working with? They model cancer drugs...last time I checked it's pretty much only big pharmas are going to be their customer.
412069: Simple for PYC, it’s share price will recover on VAL’s 201 news
davevt: The other thing it'd cretins are Unaware of is, for pyc to build these models, they have to be given data from the pharmaceutical companies they are working with. Hence it's a two way street, without the pharmas, pycs models wouldn't exist, hence why they can't charge a lot for what they are doing. Hence why when you see 'pyc has a contract', don't automatically think some company has approached them. It can be that pyc has approached them for data, and they may be able to fine tune their work or do it a bit faster. Contracts normally work like this. Pyc will approach a pharma and say let us run a simulation on one your known working drugs, one that the pharma has already worked out optimal dosing for, and see if we can get the same result using our model. Now two things happen. 1. Either their model gets the same results, in which case the pharma might use them in the future because it might have been faster or cheaper, or simply to sub out work to free up their own resources. Again this is what people don't consider...not that pyc has some 'unique' service, they don't..but a company can just use them to do work for them while they commit to other projects... Or.. 2. The model doesn't get close and pyc hopefully get some data to make their model better. This is the issue. You don't know how many clients pyc are approaching and how many no's they get or how many tests didn't work out and pycs model didn't work. End of the day, in the past 3 years they have only had 3 new clients.... But how many rejections?
davevt: Anyone notice how pycs contracts are all basically free work in the hope of some kind of cut. If they weren't doing this free work, they wouldn't be able to put out an rns. This is the point as I've mentioned countless times. Pyc doesn't care about profit, just placings and funding and trying to lift the share price. I would love to know how many companies actually APPROACH pyc..
davevt: This is what people fail to realise... It doesn't matter if EVERY SINGLE BIG PHARMA thought pycs service was AMAZING..and ALL of them wanted use pyc.. Why? Because all pyc do is dose prediction for ALREADY DESIGNED CANCER DRUGS. Now, how many cancer drugs do you think are designed and tested to work each year, by all the big pharmas combined? 3? 5? If that? Let's say 10 to be generous. Pyc dictate the doesn't matter how many billions the pharmas are worth...they ain't just throwing money at them because they have loads... Pyc charge 35 grand for a pre clinical dose schedule, and around 140 for a clinical test dose schedule...but that only happens once a pre clinical is done...and trials, which take a few years. You don't just go to pyc and go straight to a 140k clinical test.. So that's why pyc will never be more than it is.. Hence why the stupid pie in the sky claims of 'millions' could be given to pyc for their dose prediction for Doxetal for Dosemerx. Why would they get millions for something pyc charge 35k for? Yes, there could be a royalty for using it in the app, but this is merely an addition, for one single drug in an app that has thousands. This isn't some game changing thing, it's a bonus yes, but end of the day, the work pyc does doesn't command a lot of money.
Physiomics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210622 19:55:03